A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
In a randomized, controlled trial, the risk difference between groups is interpreted as a causal effect of the treatment, according to Seoyoung C. Kim, MD, ScD, MSCE, an associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital and Harvard Medical…
RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.
The Lupus and Allied Diseases Association Inc. established the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund at the Rheumatology Research Foundation, effective March 1. This fund was established to honor the life and legacy of Marc Chevrier, MD, PhD, FACR, a pioneer and patient advocate in the field of lupus. About Dr….
As we emerge from the grips of a global pandemic, we are taking this opportunity to pause and reflect on the ARP and what our division brings to the care of our patients. I found the words of Amanda Gordon’s inaugural reading of her poem, “The Hill We Climb,” inspirational and instructive for our past,…
Women remain underrepresented in research and may receive less funding than men, according to a recent study that describes differences in sex representation among U.S. National Institutes of Health study sections.
Musculoskeletal disorders pose a large burden globally, but that burden is often underappreciated. Safiri et al. set out to provide a global overview of this burden, reporting the levels and trends of prevalence, deaths and disability-adjusted life years due to musculoskeletal disorders according to age, sex and sociodemographic factors.
A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.
Younger individuals (<50 years) have a stronger genetic component in their fibromyalgia score than older individuals (>60 years), according to a study published in Arthritis & Rheumatology.1 Studies that suggest a strong familial component to fibromyalgia have often focused on individuals with primary fibromyalgia who did not have another accompanying disorder, the study authors report….
COVID-19-related deaths are significantly higher in communities with higher proportions of Black, Latinx, Asian American or other racial/ethnic minorities.